Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inactivated trivalent influenza vaccine (Shanghai Pulmonary Hospital)
- Development stage
- Unknown
- Lead developer
- Shanghai Pulmonary Hospital, Tongji University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This inactivated trivalent influenza vaccine (TIV) is being evaluated in a clinical cohort study led by Shanghai Pulmonary Hospital to determine its safety, immunogenicity, and impact on overall survival in patients with non-small cell lung cancer (NSCLC) who are undergoing treatment with PD-1 or PD-L1 inhibitors. The vaccine formulation includes inactivated antigens from two influenza A virus subtypes (H1N1 and H3N2) and one influenza B virus lineage (specifically B/Brisbane). The research aims to address clinical concerns regarding the efficacy and safety of seasonal flu vaccination in the context of immune checkpoint inhibitor therapy, ensuring that the immune stimulation from the vaccine does not negatively interact with oncological treatment or exacerbate immune-related adverse events.
- Other names
- TIVtrivalent influenza vaccine
02
Targets
HA0 (Influenza B virus hemagglutinin)
Beyond the preview
Go deeper on inactivated trivalent influenza vaccine (Shanghai Pulmonary Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inactivated trivalent influenza vaccine (Shanghai Pulmonary Hospital).